Diagnosis & Management for Better Health from Hypothyroidism

Explore effective approaches to hypothyroidism in diagnosis and management for better health and well-being.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through the complex but highly manageable world of hypothyroidism, using clear explanations and modern, evidence-based research. You will learn how the hypothalamic-pituitary-thyroid (HPT) axis works, how we distinguish primary, secondary, and tertiary hypothyroidism, and why Hashimoto’s thyroiditis and iodine balance matter. I explain how we diagnose hypothyroidism with TSH, Free T4, and antibody testing; when to treat subclinical hypothyroidism; and how thyroid imaging informs care. I also detail treatment options including levothyroxine (T4), liothyronine (T3), and desiccated thyroid extract, with a strong emphasis on a “go low and go slow” dosing strategy to avoid overtreatment and cardiometabolic risks. You will see how hypothyroidism influences cholesterol, triglycerides, and cardiovascular risk, and why restoring a euthyroid state often improves lipids.

This care occurs within a multidisciplinary, integrative model at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas. Our clinic is medically directed by Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), an internist with over 40 years of experience who serves as our Medical Director and Collaborative Physician. Together, we integrate chiropractic care, internal medicine oversight, functional medicine, personal injury care, and rehabilitation to deliver personalized, safe, and effective thyroid care for you. Throughout, I include clinical observations from my practice and publicly available case reflections (see PersonalInjuryDoctorGroup.com and my LinkedIn profile) and cite leading research to support each concept.

A Team-Based Model: Internal Medicine Oversight and Integrative Chiropractic

In our clinic, multidisciplinary collaboration is not a buzzword; it is the operating system of care.

• Medical direction and oversight: Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933), provides medical leadership, ensures diagnostic rigor, manages comorbidities, and oversees medication safety for complex endocrine and cardiometabolic cases.
• Integrative chiropractic care: I deliver evidence-informed spinal adjustments, joint and soft-tissue therapies, and neuromuscular rehabilitation to improve movement, reduce pain, and optimize autonomic balance—an essential adjunct for patients whose hypothyroidism exacerbates fatigue, stiffness, and dysautonomia.
• Functional medicine focus: We identify underlying contributors (autoimmunity, nutrient deficiencies, gut-immune dynamics, stress physiology, environmental triggers) and develop lifestyle plans that support immune regulation, metabolic resilience, and symptom relief.
• Personal injury and rehabilitation: For patients with head, neck, or spine injuries, we consider how trauma may affect the pituitary and autonomic systems, potentially contributing to secondary (central) hypothyroidism and symptom flares; we integrate measured rehab and careful return-to-activity protocols.

Why this matters: Hypothyroidism often intersects with musculoskeletal pain, dyslipidemia, insulin resistance, sleep disruption, and stress. Integrating internal medicine with chiropractic and functional medicine allows us to coordinate medication management, lifestyle changes, and neuromuscular optimization—creating a more complete path to wellness and reducing the risks of over- or under-treatment.

Thyroid Physiology Made Clear: The HPT Axis and Metabolic Control

The endocrine system carefully balances metabolism through the HPT axis:

• Hypothalamus: Releases TRH (thyrotropin-releasing hormone), signaling the pituitary.
• Pituitary gland: Secretes TSH (thyroid-stimulating hormone), which stimulates the thyroid.
• Thyroid gland: Produces T4 (thyroxine) and T3 (triiodothyronine). T4 is converted to T3, the more bioactive hormone, within tissues by deiodinase enzymes.
• Negative feedback: Rising Free T4/T3 suppress pituitary TSH, maintaining tight control—much like a thermostat and furnace.

When the thyroid fails (primary hypothyroidism), TSH rises as the pituitary “turns up the thermostat,” but the gland cannot meet demand, so Free T4 falls. In secondary (pituitary) or tertiary (hypothalamic) hypothyroidism, TSH may be inappropriately normal or low because the signaling system fails “upstream,” and the thyroid never receives the message.

Clinical relevance:

• The thyroid’s hormones regulate thermogenesis, lipid and glucose metabolism, cardiovascular function, GI motility, neuromuscular performance, and cognitive speed. Insufficient hormone action slows nearly every system, causing fatigue, weight gain, cold intolerance, bradycardia, constipation, dry skin, hair loss, and cognitive fog.

References: Chaker et al., 2017; Jonklaas et al., 2014

Classifying Hypothyroidism: Primary, Secondary, and Tertiary

• Primary hypothyroidism (thyroid gland failure)

• • Most common in iodine-sufficient regions due to Hashimoto’s thyroiditis—autoimmune destruction of thyroid tissue with TPOAb and TgAb often elevated.
  • Other causes: post-ablative or post-surgical thyroid loss, excessive iodine (Wolff-Chaikoff effect), medications (e.g., lithium, tyrosine kinase inhibitors), transient thyroiditis, and global iodine deficiency.

• Secondary hypothyroidism (pituitary dysfunction)

• • Causes: pituitary tumors, surgery or radiation, or head trauma (concussion and pituitary stalk injury).
  • Clinical observation: I have seen patients with prior concussions present years later with hormonal patterns suggestive of pituitary insufficiency—underscoring the need to ask about prior head injuries.

• Tertiary hypothyroidism (hypothalamic dysfunction)

• • Deficient TRH secretion disrupts TSH release and downstream thyroid hormone production.

References: Chaker et al., 2017; Ragusa et al., 2019

Hashimoto’s Thyroiditis and Iodine Balance: Autoimmunity and Global Context

• Hashimoto’s thyroiditis: The most common cause of primary hypothyroidism in the U.S. It involves lymphocytic infiltration, antibody-mediated interference with thyroid peroxidase (TPO) and thyroglobulin, and gradual fibrosis, leading to gland failure over time. Elevated TPOAb (85–90% of cases) and TgAb support the diagnosis (diffuse, heterogeneous ultrasound).
• Iodine deficiency: Globally, still the leading cause of hypothyroidism and goiter. In the U.S., deficiency is uncommon due to iodized salt, but over- or under-supplementation—in diets or via amiodarone and contrast agents—can disrupt normal hormone synthesis.

Why this matters: In Hashimoto’s, the question is not only “what” but “why.” We examine the immune terrain (gut health, nutrient sufficiency, environmental exposures) to identify modifiable triggers and support immune balance.

References: Ragusa et al., 2019; Brent, 2010

“Cracking the Low Thyroid Code: A Comprehensive Assessment Guide”-Video

Diagnosing Hypothyroidism: History, Exam, Labs, and Imaging

A stepwise approach ensures accuracy:

• History

• • Prior neck surgery or radiation; viral illness; postpartum status; medications (amiodarone, lithium); dietary iodine sources (kelp, supplements); family history of autoimmunity; head trauma.

• Physical examination

• • Goiter, nodules, or atrophic gland by palpation; bradycardia; delayed deep tendon reflex relaxation; myxedema (puffy face and periorbital edema); coarse, cool skin; slow wound healing; diastolic hypertension.

• Laboratory testing

• • TSH: primary screening; elevated in primary hypothyroidism.
  • Free T4: low or low-normal in hypothyroidism.
  • Antibodies: TPOAb and TgAb support autoimmune etiology.
  • Consider TSI if hyperthyroid symptoms suggest Graves’ (to differentiate).
  • Broader labs: anemia, hyperlipidemia (LDL, triglycerides), hyponatremia, elevated creatine kinase; all may reflect systemic effects of hypothyroidism.

• Imaging

• • Ultrasound: evaluates size, echotexture, and nodules. Hashimoto’s typically shows heterogeneous echotexture and small hypoechoic micronodules; atrophic patterns can reflect prior radiation or chronic autoimmune loss.

References: Chaker et al., 2017; Jonklaas et al., 2014

Subclinical Versus Overt Hypothyroidism: How We Decide to Treat

• Subclinical hypothyroidism: Elevated TSH (often 5–10 mIU/L) with normal Free T4. Symptoms vary from none to mild fatigue and weight gain. Many revert to normal, especially after transient triggers (post-illness, postpartum). However, TPOAb positivity and goiter increase the risk of progression.
• Overt hypothyroidism: Elevated TSH with low Free T4 and more pronounced symptoms; treatment is typically indicated.

Clinical decision-making:

• We treat subclinical disease selectively, weighing:

• • Symptoms and quality of life
  • TPOAb status and ultrasound findings
  • Cardiovascular risk and dyslipidemia
  • Pregnancy planning

• In older adults and those with CVD, we target conservative TSH goals to minimize arrhythmia and bone risks.

Why caution matters: Aggressive or premature treatment can push patients into iatrogenic thyrotoxicosis, raising risks of atrial fibrillation, bone loss, anxiety, and weight loss. A “go low and go slow” approach respects endocrine sensitivity and levothyroxine’s long half-life.

References: Biondi & Cooper, 2018; Cooper & Biondi, 2012

The Lipid-Thyroid Connection: Why Euthyroid First, Lipids Second

Thyroid hormones regulate HMG-CoA reductase, LDL receptor expression, and lipoprotein metabolism. Low hormone action impairs lipid handling, often producing:

• Elevated LDL cholesterol and triglycerides
• Increased VLDL and sometimes Lp(a)
• Associations with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)

Clinical sequence:

• We prioritize restoring a euthyroid state first. In my collaborations with cardiology, we consistently see lipid panels improve—sometimes normalize—once thyroid function is optimized. If dyslipidemia persists, we then target lipids directly. Treating cholesterol aggressively while hypothyroidism remains uncontrolled is often “swimming upstream.”

References: Jonklaas et al., 2014; Razvi et al., 2018; regional dyslipidemia-thyroid patterns reported in Al-Tonsi et al., 2023

Treatment Options: T4, T3, and Desiccated Thyroid Extract

• Levothyroxine (T4): First-line therapy for most patients.

• • Why it works: Mimics natural thyroid output and allows peripheral tissues to convert T4 to T3 as needed.
  • Half-life: Approximately 5–7 days—steady and forgiving.
  • Brand consistency Is Important due to the narrow therapeutic window; switching between generics can alter effective dosing. We encourage consistent formulations.

• Liothyronine (T3): Consider as an adjunct in selected patients who remain symptomatic on T4 alone.

• • Pros: Addresses impaired conversion in some cases.
  • Cons: Short half-life (~1 day), greater serum fluctuations, potential to provoke palpitations/anxiety. Requires careful, often divided dosing.

• Desiccated thyroid extract (DTE): Porcine-derived T4/T3 combination (e.g., ~38 mcg T4/9 mcg T3 per grain).

• • Considerations: Fixed T4:T3 ratio may not match human physiology. Some patients feel better on DTE; others experience hyperthyroid symptoms. Not first-line, but a rational option when monotherapy fails and under careful oversight.

References: Jonklaas et al., 2014; Chaker et al., 2017

Dosing Strategy: Go Low and Go Slow

Why this principle is crucial:

• Pharmacokinetics: Levothyroxine reaches steady state in ~5–6 half-lives; reassessment at 6–8 weeks prevents premature adjustments.
• Tissue sensitivity: Cardiac tissue is highly responsive to T3; rapid dose escalations increase the risk of tachyarrhythmias, especially in older adults or those with heart disease.
• Variable conversion: Illness, inflammation, medications (e.g., amiodarone, glucocorticoids), and nutrient status (selenium, zinc, iron) influence the conversion of T4 to T3.
• Absorption barriers: Calcium, iron, PPIs, certain fibers, and even coffee can reduce levothyroxine absorption by 20–40%.

Practical approach:

• Start at 5–25 mcg in subclinical cases or in older adults/heart disease; 25–50 mcg for many otherwise healthy adults with overt disease (rarely full replacement initially).
• Reassess TSH, Free T4, symptoms at 6–8 weeks; adjust by 5–25 mcg increments.
• Set individualized TSH targets (often ~1–3 mIU/L in younger adults; modestly higher targets, such as 2–4 mIU/L, may be safer in older adults with CVD).

References: Jonklaas et al., 2014

Medication Administration: Small Details, Big Differences

For stable levels and symptom control:

• Take levothyroxine on an empty stomach, first thing in the morning, with a full glass of water.
• Wait 45–60 minutes before eating, drinking coffee, or taking other medications.
• Separate calcium, iron, bile acid sequestrants, and certain high-fiber supplements by at least 4 hours.
• Maintain consistent brand/formulation to avoid bioavailability swings.
• Use a same-time daily routine; if adherence is an issue, we troubleshoot morning habits together.

Clinical observation: Many patients who “don’t respond” improve once we fix timing and interference errors. I routinely audit morning routines to ensure correct administration (see my practice notes and case reflections at PersonalInjuryDoctorGroup.com and my LinkedIn).

Special Topics: Amiodarone, Severe Illness, Adrenal Cautions

• Amiodarone-induced thyroid dysfunction

• • Mechanisms: high iodine load (Wolff-Chaikoff effect), direct thyroid toxicity, inhibition of deiodinases reducing T4-to-T3 conversion, and increased reverse T3.
  • Pattern: T4 may be high-normal, T3 low-normal or low; TSH varies with chronicity.
  • Management: Careful monitoring; conservative TSH targets in older adults; collaboration with cardiology to balance arrhythmia control and endocrine stability.
  • References: Bogazzi & Bartalena, 2017; Biondi & Cooper, 2018

• Severe illness and non-thyroidal illness syndrome

• • Critical illness can transiently downshift the HPT axis to conserve energy. We often “watch and wait” as patients recover before committing to long-term thyroid therapy, coordinating with endocrinology when needed.

• Adrenal insufficiency caution

• • Before initiating thyroid hormone in suspected Addison’s disease, we evaluate adrenal function. Giving thyroid hormone to a cortisol-deficient patient can precipitate an adrenal crisis. Consider autoimmune polyglandular syndromes (e.g., Schmidt’s syndrome) when antibodies or symptoms suggest multi-gland involvement.
  • Reference: Betterle et al., 2002

Case Illustrations: Bringing Concepts to Life

• Case: Subclinical Hashimoto’s in a young adult

• • Findings: TSH ~6.0 mIU/L; normal Free T4/T3; TPOAb ~1100 IU/mL; diffuse, heterogeneous goiter on ultrasound.
  • Plan: Initiated levothyroxine 25 mcg daily; six-week TSH normalized (~2.5 mIU/L) with improved energy and mood. Continued lifestyle and immune-modulating strategies: anti-inflammatory nutrition, selenium sufficiency when appropriate, stress and sleep optimization.
  • Rationale: High TPOAb and goiter increase progression risk; a low-dose therapeutic trial offers symptom relief while avoiding overtreatment.

• Case: Long-term hypothyroidism with amiodarone in an older adult

• • Context: 74-year-old male with CVD on amiodarone; taking levothyroxine 125 mcg; clinically stable; labs monitored every 6–12 months.
  • Plan: Maintain the dose; reinforce medication timing; set a conservative TSH target (often 2–4 mIU/L); coordinate with cardiology for any changes in rhythm.
  • Rationale: Avoid TSH oversuppression and arrhythmic risk; anticipate altered T4/T3 patterns on amiodarone.

• Case: Post-radiation atrophic thyroid with persistent elevation of TSH

• • Context: 52-year-old woman with prior chest radiation; on levothyroxine 112 mcg; TSH 12.0 mIU/L; ultrasound shows atrophic thyroid.
  • Plan: Verify adherence and administration; confirm formulation consistency; increase to 125 mcg; recheck in six weeks. TSH normalized; symptoms improved.
  • Rationale: Progressive gland failure requires dose titration; “go low and slow” avoids overshoot and supports cardiovascular safety.

These cases reflect patterns I commonly see in practice and that I document through my educational work (see PersonalInjuryDoctorGroup.com and my LinkedIn profile).

Integrative Chiropractic Care: Where Musculoskeletal, Autonomic, and Endocrine Systems Meet

Chiropractic care does not “treat” thyroid disease directly, but it meaningfully supports systems affected by hypothyroidism:

• Neuromuscular function and fatigue

• • Hypothyroidism can cause myopathy and slowed tendon reflex relaxation. Spinal adjustments, joint mobilization, and soft-tissue therapies reduce hypertonicity and improve movement efficiency, helping patients re-engage in exercise and daily activities with less soreness.

• Autonomic nervous system balance

• • Symptoms such as cold intolerance, constipation, and sleep disturbance often reflect sympathetic overdrive. Gentle cervical/upper thoracic techniques, diaphragmatic breathing, and vagal maneuvers support parasympathetic tone, which can improve sleep, GI motility, and perceived stress—factors that influence the HPT axis and immune balance.

• Pain modulation and quality of life

• • Chronic neck and back discomfort often worsen with hypothyroid-related stiffness. Evidence-informed manual therapies improve comfort and function, supporting adherence to therapeutic exercise and lifestyle changes.

• Lymphatic and microcirculatory support

• • Manual techniques that optimize thoracic outlet mechanics and cervical fascia glide may facilitate venous and lymphatic return, alleviating soft-tissue congestion and heaviness.

From my clinical experience in El Paso, patients who combine precise thyroid dosing with chiropractic care, nutrition, sleep, and stress management report faster improvements in energy, mood, and activity tolerance (see PersonalInjuryDoctorGroup.com and my LinkedIn for clinical observations and case discussions).

Functional Medicine Integration: Investigating Triggers and Building Resilience

Our functional medicine lens targets root contributors:

• Autoimmunity and gut-immune axis

• • We evaluate for increased intestinal permeability, dysbiosis, and nutrient malabsorption that can amplify immune activation. Dietary frameworks such as anti-inflammatory or autoimmune protocol (AIP) patterns may reduce immune triggers; we personalize based on tolerance and labs.
  • Nutrients: Ensure adequate selenium, zinc, iron, and vitamin D to support enzyme function and immune regulation; use iodine judiciously in autoimmune thyroiditis.
  • Reference: Winther et al., 2020

• Sleep and stress physiology

• • Dysregulated cortisol can impair T4-to-T3 conversion. We implement sleep hygiene, breathwork, and mindfulness to stabilize circadian rhythms and autonomic tone.

• Exercise as therapy

• • Graded, consistent activity improves insulin sensitivity, lipid profiles, and mood. Chiropractic care reduces pain barriers and improves biomechanics, enabling sustainable progress.

When We Refer to Endocrinology: Safety and Specialty Alignment

We involve endocrinology when:

• Labs and clinical reality diverge despite adherence and correct timing.
• Combination therapy (LT4 + LT3) is being considered for complex cases.
• There is a rapidly enlarging goiter, suspicious nodules, or compressive symptoms.
• Dyslipidemia or cardiovascular instability persists despite optimized thyroid status.
• Pregnancy is planned in the context of complex autoimmunity or prior complications.

Before referral, we recheck:

• Medication timing, interfering substances, and brand consistency.
• Lab assay considerations (e.g., biotin interference).
• Access and affordability barriers that may impair adherence.

Putting It All Together: A Safe, Effective, and Personalized Path

What you can expect in our integrative model:

• Comprehensive evaluation

• • Symptom mapping, thyroid labs (TSH, Free T4, Free T3, TPOAb/TgAb), lipid and metabolic panels, ultrasound when indicated, and a detailed review of medication timing and interactions.

• Stepwise treatment

• • Start with a low dose of levothyroxine where appropriate; reassess at 6–8 weeks; titrate carefully to individualized targets that prioritize symptom relief and safety.

• Lipid and cardiometabolic coordination

• • Normalize thyroid function first; then reassess lipids and cardiometabolic markers before intensifying lipid-directed therapy.

• Integrated support

• • Chiropractic care to improve mobility, autonomic balance, and pain control; functional medicine to address immune triggers and lifestyle; internal medicine oversight for safe medication management and comorbidity control.

This collaborative structure—an MD providing medical direction alongside a chiropractor—is a multidisciplinary model increasingly common in integrative and injury-care clinics. It provides the breadth of expertise necessary for nuanced, safe, and patient-centered hypothyroidism care.

References

• Al-Tonsi, A. A., Al-Hakami, A. M., & Al-Adhroey, A. H. (2023). Dyslipidemia and its associated risk factors among Yemeni patients with thyroid disorders. Vascular Health and Risk Management, 19, 235–244.
• Betterle, C., Dal Pra, C., Mantero, F., & Zanchetta, R. (2002). Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocrine Reviews, 23(3), 327–364.
• Biondi, B., & Cooper, D. S. (2018). The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews, 39(6), 834–890.
• Bogazzi, F., & Bartalena, L. (2017). Amiodarone-induced thyrotoxicosis: A review. Journal of Endocrinological Investigation, 40(2), 99–114.
• Brent, G. A. (2010). Environmental exposures and autoimmune thyroid disease. Thyroid, 20(7), 755–761.
• Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017). Hypothyroidism. The Lancet, 390(10101), 1550–1562.
• Caturegli, P., De Remigis, A., & Rose, N. R. (2014). Hashimoto thyroiditis: Clinical and diagnostic criteria. Autoimmunity Reviews, 13(4–5), 391–397.
• Cooper, D. S., & Biondi, B. (2012). Subclinical thyroid disease. Lancet, 379(9821), 1142–1154.
• Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., & Sawka, A. M. (2014). Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid, 24(12), 1670–1751.
• Ragusa, F., Fallahi, P., Elia, G., Giamberardino, M. A., Rotondi, M., & Antonelli, A. (2019). Hashimoto’s thyroiditis: from pathogenesis to treatment. Journal of Endocrinological Investigation, 42(10), 1165–1176.
• Razvi, S., Jabbar, A., Pingitore, A., Danzi, S., Biondi, B., Klein, I., & Peeters, R. (2018). Thyroid hormones and cardiovascular function and diseases. Journal of the American College of Cardiology, 71(16), 1781–1796.
• Winther, K. H., Rayman, M. P., Bonnema, S. J., & Hegedüs, L. (2020). Selenium in thyroid disorders—Essential knowledge for clinicians. Nature Reviews Endocrinology, 16(3), 165–176.

For clinical observations and additional case reflections by Dr. Alex Jimenez:

• Personal Injury Doctor Group: https://personalinjurydoctorgroup.com/
• LinkedIn: https://www.linkedin.com/in/dralexjimenez/

SEO tags: hypothyroidism, Hashimoto’s thyroiditis, thyroid antibodies, TSH, Free T4, levothyroxine dosing, liothyronine, desiccated thyroid extract, subclinical hypothyroidism, central hypothyroidism, HPT axis, amiodarone thyroid dysfunction, dyslipidemia, LDL cholesterol, triglycerides, MASLD, integrative chiropractic care, internal medicine collaboration, functional medicine thyroid, El Paso Texas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas